Plant Name: Caesalpinia sappan
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 5.923E-10 | 8.061E-07 | EGFR, ERBB2, KDR, KIT |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.845E-09 | 3.292E-06 | EGFR, ERBB2, FGFR1, KIT, MET, NOX4, SRC |
| MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 5.324E-08 | 5.270E-05 | EGFR, ERBB2, FGFR1, KIT, MET |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 1.280E-07 | 9.958E-05 | EGFR, ERBB2, FGFR1, FLT1, KIT, NOX4, SRC |
| BP | GO:0065007; biological regulation | GO:0010863; positive regulation of phospholipase C activity | 1.874E-07 | 1.317E-04 | EGFR, FGFR1, FLT1, KIT |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.304E-07 | 1.568E-04 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 3.603E-07 | 2.021E-04 | CA2, CA4, CA9, EGFR, ERBB2, HPGD |
| BP | GO:0008152; metabolic process | GO:0046854; phosphatidylinositol phosphorylation | 4.112E-07 | 2.035E-04 | EGFR, ERBB2, FGFR1, KIT, MET |
| BP | GO:0009987; cellular process | GO:2001028; positive regulation of endothelial cell chemotaxis | 9.568E-07 | 3.472E-04 | FGFR1, KDR, MET |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 1.591E-06 | 5.500E-04 | EGFR, ERBB2, FGFR1, FLT1, KDR |
| BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 1.802E-06 | 6.036E-04 | EGFR, ERBB2, FLT1, KDR, NOX4, SRC |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 3.186E-06 | 9.911E-04 | FGFR1, FLT1, KDR, KIT |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.130E-29 | 4.637E-25 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 4.060E-06 | 1.211E-03 | CA2, CA9, EGFR, FGFR1, MET, SRC |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.989E-06 | 2.002E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.215E-05 | 2.896E-03 | ALOX15, EGFR, KDR, NOX4, SRC |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 1.334E-05 | 3.091E-03 | FLT1, KIT, SRC |
| BP | GO:0009987; cellular process | GO:0038128; ERBB2 signaling pathway | 2.975E-05 | 5.943E-03 | EGFR, ERBB2, SRC |
| MF | GO:0005488; binding | GO:0019903; protein phosphatase binding | 3.208E-05 | 6.292E-03 | EGFR, ERBB2, MAPT, MET |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 3.484E-05 | 6.355E-03 | ALOX15, HPGD |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 3.484E-05 | 6.355E-03 | CA1, CA2 |
| MF | GO:0005488; binding | GO:0000166; nucleotide binding | 3.525E-05 | 6.355E-03 | ALDH1A1, EGFR, ERBB2, FGFR1, FLT1, HPGD, KDR, KIT, MET, NOX4, SRC, XDH |
| MF | GO:0098772; molecular function regulator | GO:0005088; Ras guanyl-nucleotide exchange factor activity | 3.744E-05 | 6.471E-03 | EGFR, ERBB2, FGFR1, KIT, MET |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 4.873E-05 | 7.861E-03 | FLT1, KDR |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 5.235E-05 | 8.260E-03 | EGFR, KDR, SRC |
| BP | GO:0050896; response to stimulus | GO:0032103; positive regulation of response to external stimulus | 6.429E-05 | 9.790E-03 | EGFR, FGFR1, KDR, MET, PLG |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 6.607E-05 | 9.991E-03 | ALOX15, CA2, EGFR, KDR, KIT, SRC |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.166E-22 | 1.269E-18 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.749E-21 | 2.041E-17 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.314E-28 | 1.065E-26 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 2.182E-08 | 8.836E-07 | FLT1; SRC; KIT; KDR; MET; EGFR; FGFR1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.840E-08 | 1.307E-06 | ERBB2; KIT; MET; EGFR; FGFR1 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 8.015E-08 | 1.623E-06 | SRC; ERBB2; MET; EGFR; FGFR1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 4.922E-07 | 6.644E-06 | SRC; ERBB2; KDR; MET; EGFR; FGFR1 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 4.781E-07 | 6.644E-06 | FLT1; SRC; ERBB2; KDR; MET; EGFR |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 9.461E-07 | 1.095E-05 | FLT1; KIT; KDR; MET; EGFR; FGFR1 |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 2.036E-06 | 2.062E-05 | FLT1; SRC; KIT; KDR; MET; EGFR |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 9.880E-06 | 8.892E-05 | FLT1; KIT; KDR; MET; EGFR; FGFR1 |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 4.273E-05 | 3.147E-04 | FLT1; KIT; KDR; MET; EGFR |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.124E-05 | 2.530E-04 | SRC; ERBB2; EGFR |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.844E-04 | 1.601E-03 | KIT; ERBB2; MET; EGFR; FGFR1 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 1.429E-04 | 9.646E-04 | SRC; MET; EGFR |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.625E-04 | 1.012E-03 | MET; EGFR; FGFR1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 3.170E-04 | 1.605E-03 | ERBB2; EGFR; FGFR1 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.965E-04 | 1.601E-03 | SRC; ERBB2; EGFR |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 4.868E-04 | 2.319E-03 | FLT1; ERBB2; EGFR |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.434E-03 | 1.038E-02 | FLT1; HPGD; MET |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 3.963E-03 | 1.396E-02 | SRC; EGFR; FGFR1 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 3.185E-03 | 1.229E-02 | ERBB2; EGFR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.753E-03 | 1.115E-02 | ERBB2; EGFR |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 6.450E-03 | 2.009E-02 | MAPT; EGFR; FGFR1 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 3.768E-03 | 1.387E-02 | SRC; KDR |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 4.396E-03 | 1.484E-02 | ERBB2; EGFR |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 9.785E-03 | 2.557E-02 | ERBB2; MET; EGFR |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 8.199E-03 | 2.290E-02 | SRC; EGFR |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 6.086E-03 | 1.972E-02 | SRC; MET |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 9.641E-03 | 2.557E-02 | SRC; EGFR |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 7.686E-03 | 2.223E-02 | SRC; EGFR |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.963E-02 | 4.968E-02 | KIT; EGFR |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 5.396E-04 | 2.428E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 7.478E-03 | 2.223E-02 | XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| I00-I99: Diseases of the circulatory system | Hereditary hemorrhagic telangiectasia | I78.0 | FLT1 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| I00-I99: Diseases of the circulatory system | Severe coronary heart disease | I25.1 | FGFR1 |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; ERBB2; EGFR; FGFR1 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | PLG; FLT1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; FLT1; KDR |
| H00-H59: Diseases of the eye and adnexa | Retinal venous occlusion | H34.8 | ERBB2 |
| C00-D49: Neoplasms | Liver cancer | C22 | KDR |
| NA: NA | Heart attack | NA | PLG |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | EGFR; EGFR; EGFR; KDR; KDR |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ERBB2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; SRC; CA9; ERBB2; EGFR; FGFR1; KIT; KDR; KDR; KDR |
| C00-D49: Neoplasms | Cancer | C00-C96 | PLG; MET; CA1; SRC; CA9; ERBB2; ERBB2; EGFR; FGFR1; FLT1; KIT; KDR |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | PLG |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | ERBB2; KDR |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | KIT |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; EGFR; KDR |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; ERBB2; EGFR; EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH |
| I00-I99: Diseases of the circulatory system | Pulmonary embolism | I26 | PLG |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; KDR |
| C00-D49: Neoplasms | Prostate cancer | C61 | ERBB2; EGFR |
| C00-D49: Neoplasms | HER2-positive urogenital cancer | NA | ERBB2 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PLG; PLG; PLG |
| H00-H59: Diseases of the eye and adnexa | Neovascular age-related macular degeneration | H35.3 | FLT1 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | PLG |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR; KDR; KDR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; EGFR; EGFR; KDR |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | ERBB2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; FLT1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PLG; EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| I00-I99: Diseases of the circulatory system | Chronic angina | I20 | PLG |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | FLT1 |
| H00-H59: Diseases of the eye and adnexa | Exudative age-related macular degeneration | H35.3 | FLT1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | ERBB2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC |
| H60-H95: Diseases of the ear and mastoid process | Otitis media | H65-H67 | PLG |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR; KDR; KDR; KDR; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | FGFR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PLG; MAPT |
| C00-D49: Neoplasms | AML | NA | KDR |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR; FLT1; KDR |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; FLT1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | ERBB2; EGFR; FLT1 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | PLG |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; ERBB2; ERBB2; ERBB2; EGFR; EGFR; EGFR; KDR; KDR; KDR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; EGFR; EGFR |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| NA: NA | Acute coronary thrombosis | NA | PLG |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| C00-D49: Neoplasms | Endometrial cancer | C54.1 | FGFR1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; KDR |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| I00-I99: Diseases of the circulatory system | Peripheral vascular disease | I73.9 | FLT1 |
| I00-I99: Diseases of the circulatory system | Peripheral arterial occlusive disease | I73.9 | FGFR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Excessive bleeding | R58 | PLG |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Excessive postoperative bleeding | R58 | PLG |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| C00-D49: Neoplasms | Gastric cancer | C16 | ERBB2; EGFR; EGFR; KDR; KDR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | ERBB2; EGFR; EGFR; KDR |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC |